SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA

ABSTRACT Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for >50% of patients with end-stage kidney disease. Progressive CKD leads to the requirement for...

Full description

Saved in:
Bibliographic Details
Published inNephrology, dialysis, transplantation Vol. 38; no. 11; pp. 2444 - 2455
Main Authors Mark, Patrick B, Sarafidis, Pantelis, Ekart, Robert, Ferro, Charles J, Balafa, Olga, Fernandez-Fernandez, Beatriz, Herrington, William G, Rossignol, Patrick, Del Vecchio, Lucia, Valdivielso, Jose M, Mallamaci, Francesca, Ortiz, Alberto, Nistor, Ionut, Cozzolino, Mario
Format Journal Article
LanguageEnglish
Published England Oxford University Press 31.10.2023
Subjects
Angiotensin Receptor Antagonists - therapeutic use
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Diabetes Mellitus, Type 2 - complications
Heart Failure - complications
Humans
Life Sciences
Renal Dialysis - adverse effects
Renal Insufficiency, Chronic
Review
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
diabetic kidney disease
heart failure
cardiovascular
chronic renal failure
cardiorenal syndrome
Online AccessGet full text

Cover

Abstract ABSTRACT Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for >50% of patients with end-stage kidney disease. Progressive CKD leads to the requirement for kidney replacement therapy with transplantation or dialysis. In addition, CKD, is a risk factor for premature cardiovascular disease, particularly from structural heart disease and heart failure (HF). Until 2015, the mainstay of treatment to slow progression of both diabetic and many non-diabetic kidney diseases was blood pressure control and renin-angiotensin system inhibition; however, neither angiotensin-converting enzyme inhibitors (ACEIs) nor angiotensin receptor blockers (ARBs) reduced cardiovascular events and mortality in major trials in CKD. The emergence of cardiovascular and renal benefits observed with sodium-glucose cotransporter-2 inhibitors (SGLT2i) from clinical trials of their use as anti-hyperglycaemic agents has led to a revolution in cardiorenal protection for patients with diabetes. Subsequent clinical trials, notably DAPA-HF, EMPEROR, CREDENCE, DAPA-CKD and EMPA-KIDNEY have demonstrated their benefits in reducing risk of HF and progression to kidney failure in patients with HF and/or CKD. The cardiorenal benefits—on a relative scale—appear similar in patients with or without diabetes. Specialty societies’ guidelines are continually adapting as trial data emerges to support increasingly wide use of SGLT2i. This consensus paper from EURECA-m and ERBP highlights the latest evidence and summarizes the guidelines for use of SGLT2i for cardiorenal protection focusing on benefits observed relevant to people with CKD.
AbstractList Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for >50% of patients with end-stage kidney disease. Progressive CKD leads to the requirement for kidney replacement therapy with transplantation or dialysis. In addition, CKD, is a risk factor for premature cardiovascular disease, particularly from structural heart disease and heart failure (HF). Until 2015, the mainstay of treatment to slow progression of both diabetic and many non-diabetic kidney diseases was blood pressure control and renin-angiotensin system inhibition; however, neither angiotensin-converting enzyme inhibitors (ACEIs) nor angiotensin receptor blockers (ARBs) reduced cardiovascular events and mortality in major trials in CKD. The emergence of cardiovascular and renal benefits observed with sodium-glucose cotransporter-2 inhibitors (SGLT2i) from clinical trials of their use as anti-hyperglycaemic agents has led to a revolution in cardiorenal protection for patients with diabetes. Subsequent clinical trials, notably DAPA-HF, EMPEROR, CREDENCE, DAPA-CKD and EMPA-KIDNEY have demonstrated their benefits in reducing risk of HF and progression to kidney failure in patients with HF and/or CKD. The cardiorenal benefits—on a relative scale—appear similar in patients with or without diabetes. Specialty societies’ guidelines are continually adapting as trial data emerges to support increasingly wide use of SGLT2i. This consensus paper from EURECA-m and ERBP highlights the latest evidence and summarizes the guidelines for use of SGLT2i for cardiorenal protection focusing on benefits observed relevant to people with CKD.
ABSTRACT Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for >50% of patients with end-stage kidney disease. Progressive CKD leads to the requirement for kidney replacement therapy with transplantation or dialysis. In addition, CKD, is a risk factor for premature cardiovascular disease, particularly from structural heart disease and heart failure (HF). Until 2015, the mainstay of treatment to slow progression of both diabetic and many non-diabetic kidney diseases was blood pressure control and renin-angiotensin system inhibition; however, neither angiotensin-converting enzyme inhibitors (ACEIs) nor angiotensin receptor blockers (ARBs) reduced cardiovascular events and mortality in major trials in CKD. The emergence of cardiovascular and renal benefits observed with sodium-glucose cotransporter-2 inhibitors (SGLT2i) from clinical trials of their use as anti-hyperglycaemic agents has led to a revolution in cardiorenal protection for patients with diabetes. Subsequent clinical trials, notably DAPA-HF, EMPEROR, CREDENCE, DAPA-CKD and EMPA-KIDNEY have demonstrated their benefits in reducing risk of HF and progression to kidney failure in patients with HF and/or CKD. The cardiorenal benefits—on a relative scale—appear similar in patients with or without diabetes. Specialty societies’ guidelines are continually adapting as trial data emerges to support increasingly wide use of SGLT2i. This consensus paper from EURECA-m and ERBP highlights the latest evidence and summarizes the guidelines for use of SGLT2i for cardiorenal protection focusing on benefits observed relevant to people with CKD.
Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for more than 50% of patients with end-stage kidney disease. Progressive CKD leads to the requirement for kidney replacement therapy with transplantation or dialysis. In addition, CKD, is a risk factor for premature cardiovascular disease, particularly from structural heart disease and heart failure (HF). Until 2015, the mainstay of treatment to slow progression of both diabetic and many non-diabetic kidney diseases was blood pressure control and renin-angiotensin system inhibition; however, neither angiotensin converting enzyme inhibitors (ACEIs) nor angiotensin receptor blockers (ARBs) reduced cardiovascular events and mortality in major trials in CKD. The emergence of cardiovascular and renal benefits observed with sodium-glucose cotransporter-2 inhibitors (SGLT2i) from clinical trials of their use as antihyperglycaemic agents has led to a revolution in cardiorenal protection for patients with diabetes. Subsequent clinical trials, notably DAPA-HF, EMPEROR, CREDENCE, DAPA-CKD and EMPA-KIDNEY have demonstrated their benefits in reducing risk of HF and progression to kidney failure in patients with HF and/or CKD. The cardiorenal benefits - on a relative scale - appear similar in patients with or without diabetes. Specialty societies’ guidelines are continually adapting as trial data emerges to support increasingly wide use of SGLT2i. This consensus paper from EURECA-m and ERBP highlights the latest evidence and summarises the guidelines for use of SGLT2i for cardiorenal protection focusing on benefits observed relevant to people with CKD.
Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for >50% of patients with end-stage kidney disease. Progressive CKD leads to the requirement for kidney replacement therapy with transplantation or dialysis. In addition, CKD, is a risk factor for premature cardiovascular disease, particularly from structural heart disease and heart failure (HF). Until 2015, the mainstay of treatment to slow progression of both diabetic and many non-diabetic kidney diseases was blood pressure control and renin-angiotensin system inhibition; however, neither angiotensin-converting enzyme inhibitors (ACEIs) nor angiotensin receptor blockers (ARBs) reduced cardiovascular events and mortality in major trials in CKD. The emergence of cardiovascular and renal benefits observed with sodium-glucose cotransporter-2 inhibitors (SGLT2i) from clinical trials of their use as anti-hyperglycaemic agents has led to a revolution in cardiorenal protection for patients with diabetes. Subsequent clinical trials, notably DAPA-HF, EMPEROR, CREDENCE, DAPA-CKD and EMPA-KIDNEY have demonstrated their benefits in reducing risk of HF and progression to kidney failure in patients with HF and/or CKD. The cardiorenal benefits-on a relative scale-appear similar in patients with or without diabetes. Specialty societies' guidelines are continually adapting as trial data emerges to support increasingly wide use of SGLT2i. This consensus paper from EURECA-m and ERBP highlights the latest evidence and summarizes the guidelines for use of SGLT2i for cardiorenal protection focusing on benefits observed relevant to people with CKD.Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and hypertension, which together account for >50% of patients with end-stage kidney disease. Progressive CKD leads to the requirement for kidney replacement therapy with transplantation or dialysis. In addition, CKD, is a risk factor for premature cardiovascular disease, particularly from structural heart disease and heart failure (HF). Until 2015, the mainstay of treatment to slow progression of both diabetic and many non-diabetic kidney diseases was blood pressure control and renin-angiotensin system inhibition; however, neither angiotensin-converting enzyme inhibitors (ACEIs) nor angiotensin receptor blockers (ARBs) reduced cardiovascular events and mortality in major trials in CKD. The emergence of cardiovascular and renal benefits observed with sodium-glucose cotransporter-2 inhibitors (SGLT2i) from clinical trials of their use as anti-hyperglycaemic agents has led to a revolution in cardiorenal protection for patients with diabetes. Subsequent clinical trials, notably DAPA-HF, EMPEROR, CREDENCE, DAPA-CKD and EMPA-KIDNEY have demonstrated their benefits in reducing risk of HF and progression to kidney failure in patients with HF and/or CKD. The cardiorenal benefits-on a relative scale-appear similar in patients with or without diabetes. Specialty societies' guidelines are continually adapting as trial data emerges to support increasingly wide use of SGLT2i. This consensus paper from EURECA-m and ERBP highlights the latest evidence and summarizes the guidelines for use of SGLT2i for cardiorenal protection focusing on benefits observed relevant to people with CKD.
Author Rossignol, Patrick
Sarafidis, Pantelis
Fernandez-Fernandez, Beatriz
Mark, Patrick B
Balafa, Olga
Nistor, Ionut
Ekart, Robert
Ferro, Charles J
Cozzolino, Mario
Mallamaci, Francesca
Valdivielso, Jose M
Del Vecchio, Lucia
Herrington, William G
Ortiz, Alberto
Author_xml – sequence: 1
  givenname: Patrick B
  surname: Mark
  fullname: Mark, Patrick B
  email: patrick.mark@glasgow.ac.uk
– sequence: 2
  givenname: Pantelis
  surname: Sarafidis
  fullname: Sarafidis, Pantelis
– sequence: 3
  givenname: Robert
  surname: Ekart
  fullname: Ekart, Robert
– sequence: 4
  givenname: Charles J
  surname: Ferro
  fullname: Ferro, Charles J
– sequence: 5
  givenname: Olga
  surname: Balafa
  fullname: Balafa, Olga
– sequence: 6
  givenname: Beatriz
  surname: Fernandez-Fernandez
  fullname: Fernandez-Fernandez, Beatriz
– sequence: 7
  givenname: William G
  surname: Herrington
  fullname: Herrington, William G
– sequence: 8
  givenname: Patrick
  surname: Rossignol
  fullname: Rossignol, Patrick
– sequence: 9
  givenname: Lucia
  surname: Del Vecchio
  fullname: Del Vecchio, Lucia
– sequence: 10
  givenname: Jose M
  surname: Valdivielso
  fullname: Valdivielso, Jose M
– sequence: 11
  givenname: Francesca
  surname: Mallamaci
  fullname: Mallamaci, Francesca
– sequence: 12
  givenname: Alberto
  surname: Ortiz
  fullname: Ortiz, Alberto
– sequence: 13
  givenname: Ionut
  surname: Nistor
  fullname: Nistor, Ionut
– sequence: 14
  givenname: Mario
  surname: Cozzolino
  fullname: Cozzolino, Mario
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37230946$$D View this record in MEDLINE/PubMed
https://hal.univ-lorraine.fr/hal-04107237$$DView record in HAL
BookMark eNp9kk1vEzEQQC1URNPCiTvyCYHQ0rHX-8UFhSi0SJFApT1bXns2MU3sxd6kyi_q36xDQgQcOI008_zGHs8ZOXHeISEvGbxn0OQXzgwX804ZxvgTMmKihIzndXFCRqnKMiigOSVnMf4AgIZX1TNymlc8h0aUI_Lw_XJ2wy3tfKC4sQadxqxVEQ3VKhjrAzq1pH3wA-rBeketo8aqFgerqXKGpttkx4ReBO9SvLPG4TaBEZPrA1VU-1UfcIEu2g3SkHrhPW23dHp7PZ2Ms9Uv1_T60zd678OddXM6D37dR-q7lB4_J087tYz44hDPye3n6c3kKpt9vfwyGc8yLUQ1ZF2tNBaoBG9qUEIj5HXZas5FUwF0rTEl41xXrDaCl6JEk4tOmKJtGQfDdH5OPu69_bpdodHohqCWsg92pcJWemXl3xVnF3LuN5JByYoyZ8nwdm9Y_HPuajyTuxwIBmn-1WbHvjl0C_7nGuMgVzZqXC6VQ7-OktccgBelyBP6bo_q4GMM2B3dDORuD2TaA3nYg0S_-vMZR_b3xyfg9R5IM_6v6RHD4L-Y
CitedBy_id crossref_primary_10_1093_ckj_sfae014
crossref_primary_10_1159_000538036
crossref_primary_10_1016_j_jcte_2024_100341
crossref_primary_10_1016_j_xkme_2024_100851
crossref_primary_10_1053_j_ajkd_2024_02_015
crossref_primary_10_1016_j_jacc_2024_04_013
crossref_primary_10_2174_0115734021268893231116045914
crossref_primary_10_1111_dom_15696
crossref_primary_10_1038_s41581_024_00811_7
crossref_primary_10_1093_ehjcvp_pvae003
crossref_primary_10_4093_jkd_2024_25_1_16
crossref_primary_10_1016_S2214_109X_24_00050_0
crossref_primary_10_1016_j_bjae_2024_04_007
crossref_primary_10_1038_s41598_024_61926_2
Cites_doi 10.1016/j.kint.2021.04.002
10.1016/j.jacc.2022.01.029
10.1016/S2213-8587(19)30256-6
10.1093/ndt/gfac040
10.2337/dc23-S009
10.1093/ndt/gfv100
10.1002/bdd.1909
10.1136/bmj.o775
10.1161/CIRCULATIONAHA.113.005081
10.1055/a-0958-2441
10.1093/ndt/gfab335
10.1016/j.diabres.2019.107843
10.1016/S0140-6736(22)02074-8
10.1161/CIRCULATIONAHA.121.057736
10.1016/S0140-6736(17)30550-0
10.1056/NEJMoa2204233
10.1001/jama.288.19.2421
10.1016/j.jcjd.2017.11.004
10.1016/S2213-8587(21)00243-6
10.1056/NEJMoa1504720
10.1152/physrev.00031.2005
10.1159/000506534
10.2337/dc22-0294
10.1056/NEJMoa011303
10.1056/NEJMoa2004967
10.1056/NEJMoa2022190
10.1056/NEJMoa1911303
10.1111/dom.13648
10.1161/CIRCULATIONAHA.119.044235
10.1152/ajprenal.00264.2020
10.1093/eurheartj/ehab368
10.1007/s11886-019-1165-1
10.1056/NEJMoa1515920
10.1016/j.jacc.2021.01.044
10.1056/NEJMoa1310799
10.1186/s13098-019-0454-6
10.1056/NEJMoa1415463
10.1056/NEJMoa1611925
10.1056/NEJMoa011161
10.1152/ajprenal.00689.2014
10.1159/000519812
10.1093/ckj/sfac146
10.1097/MNH.0000000000000786
10.1001/jama.2017.9362
10.1161/CIRCULATIONAHA.120.051685
10.2215/CJN.11491116
10.1056/NEJMoa2025845
10.1093/ndt/gfy407
10.1056/NEJMoa1812389
10.1093/ndt/gfab167
10.1093/eurheartj/ehab777
10.1056/NEJMoa041031
10.1056/NEJMoa2107038
10.1016/S2213-8587(20)30382-X
10.1056/NEJMoa2206286
10.1016/S0140-6736(10)60674-5
10.1093/ndt/gfaa329
10.1681/ASN.2019010064
10.1093/ndt/gfz174
10.1681/ASN.2012070718
10.1056/NEJMoa2024816
10.1016/j.eclinm.2021.101163
10.1056/NEJMoa1811744
10.1038/ajh.2008.206
10.1093/ckj/sfy090
10.1161/CIRCULATIONAHA.117.028268
10.1172/jci.insight.98720
10.1016/S0140-6736(16)30508-6
10.2337/dci22-0034
10.1093/eurheartj/ehz486
10.1038/s41598-018-25054-y
10.1016/j.kint.2021.03.033
10.1093/ndt/gfaa234
10.1172/jci.insight.129034
10.1056/NEJMoa2110956
10.1016/j.kint.2022.06.008
ContentType Journal Article
Copyright The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. 2023
The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
Attribution - NonCommercial
Copyright_xml – notice: The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. 2023
– notice: The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
– notice: Attribution - NonCommercial
DBID TOX
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
1XC
VOOES
5PM
DOI 10.1093/ndt/gfad112
DatabaseName Oxford Open (Open Access)
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Hyper Article en Ligne (HAL)
Hyper Article en Ligne (HAL) (Open Access)
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
CrossRef

MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: TOX
  name: Oxford Academic Journals (Open Access)
  url: https://academic.oup.com/journals/
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1460-2385
EndPage 2455
ExternalDocumentID oai_HAL_hal_04107237v1
10_1093_ndt_gfad112
37230946
10.1093/ndt/gfad112
Genre Journal Article
Review
GrantInformation_xml – fundername: Medical Research Council
  grantid: MC_UU_00017/3
– fundername: Medical Research Council
  grantid: MR/R007764/1
– fundername: ;
– fundername: ;
  grantid: PI18/01366; PI19/00588; PI19/00815; PI21/00251; PI20/00744
– fundername: ;
  grantid: RD21/0005/0001
GroupedDBID ---
-E4
.2P
.55
.GJ
.I3
.XZ
.ZR
0R~
123
18M
1TH
29M
2WC
4.4
482
48X
53G
5RE
5VS
5WA
5WD
6.Y
70D
AABZA
AACZT
AAHTB
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AASNB
AAUAY
AAUQX
AAVAP
AAWDT
ABEUO
ABIXL
ABJNI
ABKDP
ABNHQ
ABNKS
ABOCM
ABPEJ
ABPTD
ABQLI
ABQNK
ABQTQ
ABSAR
ABSMQ
ABWST
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACMRT
ACPQN
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ACZBC
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKPW
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFSHK
AFXAL
AFXEN
AFYAG
AGINJ
AGKEF
AGKRT
AGMDO
AGQXC
AGSYK
AGUTN
AHMBA
AHXPO
AIAGR
AIJHB
AJEEA
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APJGH
APWMN
AQDSO
AQKUS
ASPBG
ATGXG
ATTQO
AVNTJ
AVWKF
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
BZKNY
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EIHJH
EJD
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
JXSIZ
KAQDR
KBUDW
KC5
KOP
KQ8
KSI
KSN
M-Z
M49
MBLQV
MHKGH
ML0
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
P6G
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RNI
ROL
ROX
ROZ
RUSNO
RW1
RXO
RZF
RZO
SDH
TCURE
TEORI
TJX
TMA
TOX
TR2
W8F
WH7
WOQ
X7H
X7M
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZXP
~91
ABEJV
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
1XC
VOOES
5PM
ID FETCH-LOGICAL-c447t-f8ace5ea42980a4ce0386bc2249700fbdd6122c718d42646ed34f4d5bb120d1c3
IEDL.DBID TOX
ISSN 0931-0509
1460-2385
IngestDate Tue Sep 17 21:29:23 EDT 2024
Tue Oct 15 15:37:56 EDT 2024
Sat Oct 26 02:03:02 EDT 2024
Thu Sep 12 17:53:23 EDT 2024
Sat Nov 02 12:22:33 EDT 2024
Wed Aug 28 03:17:54 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords diabetic kidney disease
heart failure
cardiovascular
chronic renal failure
cardiorenal syndrome
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
Attribution - NonCommercial: http://creativecommons.org/licenses/by-nc
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c447t-f8ace5ea42980a4ce0386bc2249700fbdd6122c718d42646ed34f4d5bb120d1c3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ORCID 0000-0002-9805-9523
0000-0002-8494-6252
0000-0002-9174-4018
0000-0003-0577-7081
0000-0003-1343-0184
0000-0001-8009-3873
OpenAccessLink https://dx.doi.org/10.1093/ndt/gfad112
PMID 37230946
PQID 2820025643
PQPubID 23479
PageCount 12
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10615631
hal_primary_oai_HAL_hal_04107237v1
proquest_miscellaneous_2820025643
crossref_primary_10_1093_ndt_gfad112
pubmed_primary_37230946
oup_primary_10_1093_ndt_gfad112
PublicationCentury 2000
PublicationDate 2023-10-31
PublicationDateYYYYMMDD 2023-10-31
PublicationDate_xml – month: 10
  year: 2023
  text: 2023-10-31
  day: 31
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Nephrology, dialysis, transplantation
PublicationTitleAlternate Nephrol Dial Transplant
PublicationYear 2023
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Wheeler (2023103100564683200_bib36) 2020; 35
Zannad (2023103100564683200_bib52) 2021; 143
ElSayed (2023103100564683200_bib70) 2023; 46
Ortiz (2023103100564683200_bib7) 2023; 38
Inoue (2023103100564683200_bib33) 2019; 11
Gregg (2023103100564683200_bib13) 2014; 370
Mark (2023103100564683200_bib54) 2022; 15
Rauen (2023103100564683200_bib44) 2015; 373
Rossing (2023103100564683200_bib62) 2022; 45
Cosentino (2023103100564683200_bib71) 2019; 41
Neuen (2023103100564683200_bib63) 2022; 145
Staplin (2023103100564683200_bib19) 2021; 41
(2023103100564683200_bib78) 2022
2023103100564683200_bib77
Neuen (2023103100564683200_bib55) 2019; 7
Wheeler (2023103100564683200_bib39) 2021; 100
Cannon (2023103100564683200_bib80) 2020; 383
Heerspink (2023103100564683200_bib35) 2020; 383
Ferreira (2023103100564683200_bib65) 2021; 77
Moran (2023103100564683200_bib76) 2022; 377
Li (2023103100564683200_bib34) 2020; 5
Fellstrom (2023103100564683200_bib43) 2017; 389
Solomon (2023103100564683200_bib53) 2022; 387
Go (2023103100564683200_bib9) 2004; 351
Barratt (2023103100564683200_bib47) 2021; 100
Vallon (2023103100564683200_bib21) 2006; 86
Jongs (2023103100564683200_bib37) 2021; 9
Mazer (2023103100564683200_bib27) 2020; 141
Packer (2023103100564683200_bib50) 2020; 383
Alicic (2023103100564683200_bib2) 2017; 12
Saeedi (2023103100564683200_bib3) 2019; 157
Wanner (2023103100564683200_bib14) 2016; 375
Perkovic (2023103100564683200_bib18) 2019; 380
Wheeler (2023103100564683200_bib40) 2022; 37
Neuen (2023103100564683200_bib16) 2019; 30
Umino (2023103100564683200_bib32) 2018; 8
Group (2023103100564683200_bib57) 2022; 37
Onishi (2023103100564683200_bib23) 2020; 319
Shen (2023103100564683200_bib66) 2021; 9
McMurray (2023103100564683200_bib49) 2019; 381
Sarafidis (2023103100564683200_bib74) 2019; 34
McDonagh (2023103100564683200_bib72) 2021; 42
Brenner (2023103100564683200_bib4) 2001; 345
Matsushita (2023103100564683200_bib10) 2010; 375
Wanner (2023103100564683200_bib11) 2016; 388
Scheen (2023103100564683200_bib25) 2019; 21
Cassis (2023103100564683200_bib29) 2018; 3
McQuarrie (2023103100564683200_bib79) 2022; 31
ERBP (2023103100564683200_bib73) 2015; 30
Packer (2023103100564683200_bib30) 2020; 51
Neal (2023103100564683200_bib17) 2017; 377
Cherney (2023103100564683200_bib22) 2014; 129
McFarlane (2023103100564683200_bib68) 2018; 42
Herrington (2023103100564683200_bib38) 2018; 11
Pitt (2023103100564683200_bib60) 2021; 385
Afkarian (2023103100564683200_bib12) 2013; 24
Jager (2023103100564683200_bib1) 2019; 34
Chino (2023103100564683200_bib28) 2014; 35
Wu (2023103100564683200_bib31) 2019; 51
Jensen (2023103100564683200_bib24) 2021; 9
Zinman (2023103100564683200_bib48) 2015; 373
Wright (2023103100564683200_bib6) 2002; 288
Lewis (2023103100564683200_bib5) 2001; 345
O'Neill (2023103100564683200_bib26) 2015; 309
Anders (2023103100564683200_bib46) 2022; 37
Lv (2023103100564683200_bib42) 2017; 318
Toyama (2023103100564683200_bib64) 2019; 21
Sarafidis (2023103100564683200_bib8) 2008; 21
Wong (2023103100564683200_bib41) 2021; 52
Davies (2023103100564683200_bib69) 2022; 45
Herrington (2023103100564683200_bib58) 2023; 388
Bakris (2023103100564683200_bib59) 2020; 383
Rossing (2023103100564683200_bib75) 2022; 102
Ferreira (2023103100564683200_bib67) 2022; 79
Wanner (2023103100564683200_bib15) 2018; 137
Baigent (2023103100564683200_bib45) 2022; 400
Anker (2023103100564683200_bib51) 2021; 385
(2023103100564683200_bib56) 2022; 388
Agarwal (2023103100564683200_bib61) 2022; 43
Wiviott (2023103100564683200_bib20) 2019; 380
References_xml – volume: 388
  start-page: 117
  year: 2022
  ident: 2023103100564683200_bib56
  article-title: The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C et al. Empagliflozin in patients with chronic kidney disease
  publication-title: N Engl J Med
– volume: 100
  start-page: 24
  year: 2021
  ident: 2023103100564683200_bib47
  article-title: SGLT-2 inhibition in IgA nephropathy: the new standard of care?
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2021.04.002
  contributor:
    fullname: Barratt
– volume: 79
  start-page: 1129
  year: 2022
  ident: 2023103100564683200_bib67
  article-title: Mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2022.01.029
  contributor:
    fullname: Ferreira
– volume: 7
  start-page: 845
  year: 2019
  ident: 2023103100564683200_bib55
  article-title: SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/S2213-8587(19)30256-6
  contributor:
    fullname: Neuen
– volume: 37
  start-page: 1317
  year: 2022
  ident: 2023103100564683200_bib57
  article-title: Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfac040
  contributor:
    fullname: Group
– volume: 46
  start-page: S140
  year: 2023
  ident: 2023103100564683200_bib70
  article-title: 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023
  publication-title: Diabetes Care
  doi: 10.2337/dc23-S009
  contributor:
    fullname: ElSayed
– volume: 30
  start-page: ii1
  year: 2015
  ident: 2023103100564683200_bib73
  article-title: Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min)
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfv100
  contributor:
    fullname: ERBP
– volume: 35
  start-page: 391
  year: 2014
  ident: 2023103100564683200_bib28
  article-title: SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
  publication-title: Biopharm Drug Dispos
  doi: 10.1002/bdd.1909
  contributor:
    fullname: Chino
– volume: 377
  start-page: o775
  year: 2022
  ident: 2023103100564683200_bib76
  article-title: Type 2 diabetes: summary of updated NICE guidance
  publication-title: BMJ
  doi: 10.1136/bmj.o775
  contributor:
    fullname: Moran
– volume: 129
  start-page: 587
  year: 2014
  ident: 2023103100564683200_bib22
  article-title: Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.113.005081
  contributor:
    fullname: Cherney
– volume: 51
  start-page: 487
  year: 2019
  ident: 2023103100564683200_bib31
  article-title: Systematic review and meta-analysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes
  publication-title: Horm Metab Res
  doi: 10.1055/a-0958-2441
  contributor:
    fullname: Wu
– volume: 37
  start-page: 1647
  year: 2022
  ident: 2023103100564683200_bib40
  article-title: Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the DAPA-CKD trial
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfab335
  contributor:
    fullname: Wheeler
– volume: 157
  start-page: 107843
  year: 2019
  ident: 2023103100564683200_bib3
  article-title: Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition.
  publication-title: Diabetes Res Clin Pract
  doi: 10.1016/j.diabres.2019.107843
  contributor:
    fullname: Saeedi
– volume: 400
  start-page: 1788
  year: 2022
  ident: 2023103100564683200_bib45
  article-title: Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
  publication-title: Lancet North Am Ed
  doi: 10.1016/S0140-6736(22)02074-8
  contributor:
    fullname: Baigent
– volume: 145
  start-page: 1460
  year: 2022
  ident: 2023103100564683200_bib63
  article-title: Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.121.057736
  contributor:
    fullname: Neuen
– volume: 389
  start-page: 2117
  year: 2017
  ident: 2023103100564683200_bib43
  article-title: Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
  publication-title: Lancet North Am Ed
  doi: 10.1016/S0140-6736(17)30550-0
  contributor:
    fullname: Fellstrom
– volume: 388
  start-page: 117
  year: 2023
  ident: 2023103100564683200_bib58
  article-title: Empagliflozin in patients with chronic kidney disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2204233
  contributor:
    fullname: Herrington
– volume: 288
  start-page: 2421
  year: 2002
  ident: 2023103100564683200_bib6
  article-title: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial
  publication-title: JAMA
  doi: 10.1001/jama.288.19.2421
  contributor:
    fullname: Wright
– volume: 42
  start-page: S201
  year: 2018
  ident: 2023103100564683200_bib68
  article-title: Chronic kidney disease in diabetes
  publication-title: Can J Diabetes
  doi: 10.1016/j.jcjd.2017.11.004
  contributor:
    fullname: McFarlane
– volume: 9
  start-page: 755
  year: 2021
  ident: 2023103100564683200_bib37
  article-title: Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/S2213-8587(21)00243-6
  contributor:
    fullname: Jongs
– volume: 373
  start-page: 2117
  year: 2015
  ident: 2023103100564683200_bib48
  article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1504720
  contributor:
    fullname: Zinman
– volume: 86
  start-page: 901
  year: 2006
  ident: 2023103100564683200_bib21
  article-title: Adenosine and kidney function
  publication-title: Physiol Rev
  doi: 10.1152/physrev.00031.2005
  contributor:
    fullname: Vallon
– volume: 51
  start-page: 289
  year: 2020
  ident: 2023103100564683200_bib30
  article-title: Mitigation of the adverse consequences of nutrient excess on the kidney: a unified hypothesis to explain the renoprotective effects of sodium-glucose cotransporter 2 inhibitors
  publication-title: Am J Nephrol
  doi: 10.1159/000506534
  contributor:
    fullname: Packer
– volume: 45
  start-page: 2991
  year: 2022
  ident: 2023103100564683200_bib62
  article-title: Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY Analysis
  publication-title: Diabetes Care
  doi: 10.2337/dc22-0294
  contributor:
    fullname: Rossing
– volume: 345
  start-page: 851
  year: 2001
  ident: 2023103100564683200_bib5
  article-title: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa011303
  contributor:
    fullname: Lewis
– volume: 383
  start-page: 1425
  year: 2020
  ident: 2023103100564683200_bib80
  article-title: Cardiovascular outcomes with ertugliflozin in Type 2 diabetes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2004967
  contributor:
    fullname: Cannon
– volume: 383
  start-page: 1413
  year: 2020
  ident: 2023103100564683200_bib50
  article-title: Cardiovascular and renal outcomes with empagliflozin in heart failure
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2022190
  contributor:
    fullname: Packer
– volume: 381
  start-page: 1995
  year: 2019
  ident: 2023103100564683200_bib49
  article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1911303
  contributor:
    fullname: McMurray
– volume: 21
  start-page: 1237
  year: 2019
  ident: 2023103100564683200_bib64
  article-title: Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.13648
  contributor:
    fullname: Toyama
– volume: 141
  start-page: 704
  year: 2020
  ident: 2023103100564683200_bib27
  article-title: Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.119.044235
  contributor:
    fullname: Mazer
– volume: 319
  start-page: F712
  year: 2020
  ident: 2023103100564683200_bib23
  article-title: A role for tubular Na(+)/H(+) exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin
  publication-title: Am J Physiol Renal Physiol
  doi: 10.1152/ajprenal.00264.2020
  contributor:
    fullname: Onishi
– volume: 42
  start-page: 3599
  year: 2021
  ident: 2023103100564683200_bib72
  article-title: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehab368
  contributor:
    fullname: McDonagh
– volume: 21
  start-page: 70
  year: 2019
  ident: 2023103100564683200_bib25
  article-title: Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure
  publication-title: Curr Cardiol Rep
  doi: 10.1007/s11886-019-1165-1
  contributor:
    fullname: Scheen
– volume: 375
  start-page: 323
  year: 2016
  ident: 2023103100564683200_bib14
  article-title: Empagliflozin and progression of kidney disease in type 2 diabetes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1515920
  contributor:
    fullname: Wanner
– volume: 77
  start-page: 1397
  year: 2021
  ident: 2023103100564683200_bib65
  article-title: Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: eMPEROR-reduced
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2021.01.044
  contributor:
    fullname: Ferreira
– volume: 370
  start-page: 1514
  year: 2014
  ident: 2023103100564683200_bib13
  article-title: Changes in diabetes-related complications in the United States, 1990–2010
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1310799
  contributor:
    fullname: Gregg
– volume: 11
  start-page: 57
  year: 2019
  ident: 2023103100564683200_bib33
  article-title: Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice
  publication-title: Diabetol Metab Syndr
  doi: 10.1186/s13098-019-0454-6
  contributor:
    fullname: Inoue
– volume: 9
  start-page: 254
  year: 2021
  ident: 2023103100564683200_bib66
  article-title: Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF
  publication-title: JACC: Heart Failure
  contributor:
    fullname: Shen
– volume: 373
  start-page: 2225
  year: 2015
  ident: 2023103100564683200_bib44
  article-title: Intensive supportive care plus immunosuppression in IgA nephropathy
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1415463
  contributor:
    fullname: Rauen
– volume: 377
  start-page: 644
  year: 2017
  ident: 2023103100564683200_bib17
  article-title: Canagliflozin and cardiovascular and renal events in type 2 diabetes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1611925
  contributor:
    fullname: Neal
– volume: 345
  start-page: 861
  year: 2001
  ident: 2023103100564683200_bib4
  article-title: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa011161
  contributor:
    fullname: Brenner
– volume: 309
  start-page: F227
  year: 2015
  ident: 2023103100564683200_bib26
  article-title: Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats
  publication-title: Am J Physiol Renal Physiol
  doi: 10.1152/ajprenal.00689.2014
  contributor:
    fullname: O'Neill
– volume: 52
  start-page: 827
  year: 2021
  ident: 2023103100564683200_bib41
  article-title: The therapeutic evaluation of steroids in IgA Nephropathy Global (TESTING) Study: trial design and baseline characteristics
  publication-title: Am J Nephrol
  doi: 10.1159/000519812
  contributor:
    fullname: Wong
– volume: 15
  start-page: 2186
  year: 2022
  ident: 2023103100564683200_bib54
  article-title: Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients
  publication-title: Clin Kidney J
  doi: 10.1093/ckj/sfac146
  contributor:
    fullname: Mark
– volume: 31
  start-page: 272
  year: 2022
  ident: 2023103100564683200_bib79
  article-title: Seven suggestions for successful SGLT2i use in glomerular disease - a standalone CKD therapy?
  publication-title: Curr Opin Nephrol Hypertens
  doi: 10.1097/MNH.0000000000000786
  contributor:
    fullname: McQuarrie
– volume: 318
  start-page: 432
  year: 2017
  ident: 2023103100564683200_bib42
  article-title: Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING Randomized Clinical Trial
  publication-title: J Am Med Assoc
  doi: 10.1001/jama.2017.9362
  contributor:
    fullname: Lv
– volume: 143
  start-page: 310
  year: 2021
  ident: 2023103100564683200_bib52
  article-title: Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.120.051685
  contributor:
    fullname: Zannad
– volume: 12
  start-page: 2032
  year: 2017
  ident: 2023103100564683200_bib2
  article-title: Diabetic kidney disease: challenges, progress, and possibilities
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.11491116
  contributor:
    fullname: Alicic
– volume: 383
  start-page: 2219
  year: 2020
  ident: 2023103100564683200_bib59
  article-title: Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2025845
  contributor:
    fullname: Bakris
– volume: 34
  start-page: 208
  year: 2019
  ident: 2023103100564683200_bib74
  article-title: SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfy407
  contributor:
    fullname: Sarafidis
– ident: 2023103100564683200_bib77
– volume: 380
  start-page: 347
  year: 2019
  ident: 2023103100564683200_bib20
  article-title: Dapagliflozin and cardiovascular outcomes in type 2 diabetes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1812389
  contributor:
    fullname: Wiviott
– volume: 38
  start-page: 10
  year: 2023
  ident: 2023103100564683200_bib7
  article-title: Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfab167
  contributor:
    fullname: Ortiz
– volume: 43
  start-page: 474
  year: 2022
  ident: 2023103100564683200_bib61
  article-title: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehab777
  contributor:
    fullname: Agarwal
– volume: 351
  start-page: 1296
  year: 2004
  ident: 2023103100564683200_bib9
  article-title: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa041031
  contributor:
    fullname: Go
– volume: 385
  start-page: 1451
  year: 2021
  ident: 2023103100564683200_bib51
  article-title: Empagliflozin in heart failure with a preserved ejection fraction
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2107038
  contributor:
    fullname: Anker
– volume: 9
  start-page: 106
  year: 2021
  ident: 2023103100564683200_bib24
  article-title: Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/S2213-8587(20)30382-X
  contributor:
    fullname: Jensen
– year: 2022
  ident: 2023103100564683200_bib78
– volume: 387
  start-page: 1089
  year: 2022
  ident: 2023103100564683200_bib53
  article-title: Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2206286
  contributor:
    fullname: Solomon
– volume: 375
  start-page: 2073
  year: 2010
  ident: 2023103100564683200_bib10
  article-title: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)60674-5
  contributor:
    fullname: Matsushita
– volume: 37
  start-page: 1609
  year: 2022
  ident: 2023103100564683200_bib46
  article-title: SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, ‘diabetic nephropathy’, IgA nephropathy and podocytopathies with FSGS lesions
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfaa329
  contributor:
    fullname: Anders
– volume: 30
  start-page: 2229
  year: 2019
  ident: 2023103100564683200_bib16
  article-title: Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS Program
  publication-title: JASN
  doi: 10.1681/ASN.2019010064
  contributor:
    fullname: Neuen
– volume: 34
  start-page: 1803
  year: 2019
  ident: 2023103100564683200_bib1
  article-title: A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfz174
  contributor:
    fullname: Jager
– volume: 24
  start-page: 302
  year: 2013
  ident: 2023103100564683200_bib12
  article-title: Kidney disease and increased mortality risk in type 2 diabetes
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2012070718
  contributor:
    fullname: Afkarian
– volume: 383
  start-page: 1436
  year: 2020
  ident: 2023103100564683200_bib35
  article-title: Dapagliflozin in patients with chronic kidney disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2024816
  contributor:
    fullname: Heerspink
– volume: 41
  start-page: 101163
  year: 2021
  ident: 2023103100564683200_bib19
  article-title: Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2021.101163
  contributor:
    fullname: Staplin
– volume: 380
  start-page: 2295
  year: 2019
  ident: 2023103100564683200_bib18
  article-title: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1811744
  contributor:
    fullname: Perkovic
– volume: 21
  start-page: 922
  year: 2008
  ident: 2023103100564683200_bib8
  article-title: Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis
  publication-title: Am J Hypertens
  doi: 10.1038/ajh.2008.206
  contributor:
    fullname: Sarafidis
– volume: 11
  start-page: 749
  year: 2018
  ident: 2023103100564683200_bib38
  article-title: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
  publication-title: Clin Kidney J
  doi: 10.1093/ckj/sfy090
  contributor:
    fullname: Herrington
– volume: 137
  start-page: 119
  year: 2018
  ident: 2023103100564683200_bib15
  article-title: Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.117.028268
  contributor:
    fullname: Wanner
– volume: 3
  start-page: e98720
  year: 2018
  ident: 2023103100564683200_bib29
  article-title: SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.98720
  contributor:
    fullname: Cassis
– volume: 388
  start-page: 276
  year: 2016
  ident: 2023103100564683200_bib11
  article-title: The heart and vascular system in dialysis
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)30508-6
  contributor:
    fullname: Wanner
– volume: 45
  start-page: 2753
  year: 2022
  ident: 2023103100564683200_bib69
  article-title: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
  publication-title: Diabetes Care
  doi: 10.2337/dci22-0034
  contributor:
    fullname: Davies
– volume: 41
  start-page: 255
  year: 2019
  ident: 2023103100564683200_bib71
  article-title: 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehz486
  contributor:
    fullname: Cosentino
– volume: 8
  start-page: 6791
  year: 2018
  ident: 2023103100564683200_bib32
  article-title: High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-25054-y
  contributor:
    fullname: Umino
– volume: 100
  start-page: 215
  year: 2021
  ident: 2023103100564683200_bib39
  article-title: A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2021.03.033
  contributor:
    fullname: Wheeler
– volume: 35
  start-page: 1700
  year: 2020
  ident: 2023103100564683200_bib36
  article-title: The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfaa234
  contributor:
    fullname: Wheeler
– volume: 5
  start-page: e129034
  year: 2020
  ident: 2023103100564683200_bib34
  article-title: Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.129034
  contributor:
    fullname: Li
– volume: 385
  start-page: 2252
  year: 2021
  ident: 2023103100564683200_bib60
  article-title: Cardiovascular events with finerenone in kidney disease and type 2 diabetes
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2110956
  contributor:
    fullname: Pitt
– volume: 102
  start-page: S1
  year: 2022
  ident: 2023103100564683200_bib75
  article-title: KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2022.06.008
  contributor:
    fullname: Rossing
SSID ssj0009277
Score 2.5778248
SecondaryResourceType review_article
Snippet ABSTRACT Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes...
Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850 million people globally. The leading causes of CKD is diabetes and...
SourceID pubmedcentral
hal
proquest
crossref
pubmed
oup
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 2444
SubjectTerms Angiotensin Receptor Antagonists - therapeutic use
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Diabetes Mellitus, Type 2 - complications
Heart Failure - complications
Humans
Life Sciences
Renal Dialysis - adverse effects
Renal Insufficiency, Chronic
Review
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Title SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA
URI https://www.ncbi.nlm.nih.gov/pubmed/37230946
https://www.proquest.com/docview/2820025643
https://hal.univ-lorraine.fr/hal-04107237
https://pubmed.ncbi.nlm.nih.gov/PMC10615631
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELZoD4gL4k14tAPq1Wr8iDfb21Jtu0ItoLIr7S2KX2yESNHulqq_iL_JOHaXpqrg6sQjO5-jmfHMfEPInnDM5rXkgQpR0UB4R8vSOWq1D93jBiYSmJ5-UpOZ_Dgv5ilBdnVHCH8o9lu73v_ma8u6ZsKBEA2P7fTz_C-3Lu8aLOK76BmjAkxleLfm9hTP1iKkPfZK2m5YlrcTJG9onKNH5GEyFWEUsX1M7rn2Cbl_moLhT8nvr8cnU94Amp3gUnNQGrSSBdNlmS5dmJ-YGPD7Q9NCvGttDNStBXT96WbARJpc-N7Y1l1BitwcQA0h7XzpFjHVHWKxC-grGM_Oxocj-qOTNT778AUu49U7dLUiKzj3ODx6RmZH4-nhhKa-C9RIOVhTX9bGFQ4RHJaIY-goViptUNkPB3nutbVoFnGDWs0Ge0o5K6SXttCa8dwyI56TbdyAe0lAG3S9ayWtZ0PJvdGlKZgrlFFKc1_yjOxdg1L9jPQaVQyLiwqxqxJ2GXmPgG3eCJTYk9FJFcZyiQ4sF4NfLCO7uLd_i3l3jXWFf1EIjdStO79YVeh4dtafFBl5EbHfCBIoHp1glZGydyp6y-k_aZtFx9Qd_O1CCfbqv0t7TR6ERvZRK74h2-vlhXuL5s5a75Ct4znb6Y78H8rE_2s
link.rule.ids 230,315,783,787,888,1607,27936,27937
linkProvider Oxford University Press
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SGLT2i+for+evidence-based+cardiorenal+protection+in+diabetic+and+non-diabetic+chronic+kidney+disease%3A+a+comprehensive+review+by+EURECA-m+and+ERBP+working+groups+of+ERA&rft.jtitle=Nephrology%2C+dialysis%2C+transplantation&rft.au=Mark%2C+Patrick+B&rft.au=Sarafidis%2C+Pantelis&rft.au=Ekart%2C+Robert&rft.au=Ferro%2C+Charles+J&rft.date=2023-10-31&rft.issn=0931-0509&rft.eissn=1460-2385&rft.volume=38&rft.issue=11&rft.spage=2444&rft.epage=2455&rft_id=info:doi/10.1093%2Fndt%2Fgfad112&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_ndt_gfad112
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0931-0509&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0931-0509&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0931-0509&client=summon